Dual-Status Plan B Would Establish Two Distinct New Drugs – Barr
This article was originally published in The Tan Sheet
Executive Summary
An FDA rulemaking on dual-status drugs is unnecessary because approving the Plan B switch application with an age restriction would constitute approval of two separate products, according to Barr Labs